Q3 2025 · 13F-HR
SILVERARC CAPITAL MANAGEMENT, LLCholdings as filed
Filed 2025-11-12 · accession 0001420506-25-003142
$741.6M
Reported value
82
Positions
2025-09-30
Period end
The Brief · SILVERARC CAPITAL MANAGEMENT, LLC · Q3 2025
AI · grounded in 13F
Silverarc Capital Management, LLC closed its position in Merus N V 2GH, reducing exposure by $39.0M. The fund established new positions in ABIVAX SA ABVX for $45.8M and United Therapeutics Corp Del UTHR for $25.1M. Additionally, the manager increased its holdings in UniQure NV QURE by 124.6% and Avidity Biosciences Inc RNAGBP by 106.0%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00370M103 | ABVX | ABIVAX SA | $45.8M | 6.18% | 539,704 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $37.4M | 5.04% | 369,996 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $36.8M | 4.96% | 844,633 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $32.2M | 4.34% | 372,300 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $31.5M | 4.24% | 1,577,283 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $30.6M | 4.12% | 643,636 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $29.8M | 4.01% | 206,648 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $26.6M | 3.58% | 674,966 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $26.6M | 3.58% | 455,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $25.7M | 3.47% | 638,346 | Common | SOLE |
| 91307C952 | UTHR | UNITED THERAPEUTICS CORP DEL | $25.1M | 3.39% | 59,900 | PUT | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $23.4M | 3.15% | 1,948,808 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $21.2M | 2.85% | 220,902 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $16.9M | 2.27% | 10,600,000 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $16.6M | 2.24% | 1,363,378 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $16.4M | 2.21% | 1,000,000 | Common | SOLE |
| 90400D908 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $15.9M | 2.14% | 528,200 | CALL | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $12.6M | 1.69% | 4,779,082 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $11.7M | 1.58% | 815,075 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $11.6M | 1.56% | 211,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $11.3M | 1.53% | 314,339 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $11.3M | 1.52% | 80,419 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $10.6M | 1.44% | 53,554 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $9.9M | 1.34% | 2,833,988 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $9.5M | 1.28% | 700,000 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $9.2M | 1.24% | 1,042,757 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $9.2M | 1.24% | 720,922 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $9.1M | 1.23% | 933,541 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $9.0M | 1.22% | 348,922 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $8.7M | 1.17% | 233,920 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $8.1M | 1.09% | 235,791 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $7.1M | 0.96% | 463,708 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $6.1M | 0.82% | 203,946 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $5.6M | 0.76% | 259,509 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $5.4M | 0.73% | 180,513 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $5.4M | 0.73% | 588,789 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $5.3M | 0.71% | 457,414 | Common | SOLE |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $5.3M | 0.71% | 994,754 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $5.2M | 0.70% | 778,611 | Common | SOLE |
| 19240Q901 | COGT | COGENT BIOSCIENCES INC | $5.2M | 0.70% | 360,000 | CALL | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $5.1M | 0.69% | 694,942 | Common | SOLE |
| M25722105 | CGEN | COMPUGEN LTD | $4.9M | 0.66% | 3,311,165 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $4.6M | 0.62% | 183,903 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $4.4M | 0.59% | 88,686 | Common | SOLE |
| 157085101 | CERS | CERUS CORP | $4.3M | 0.58% | 2,715,786 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $4.2M | 0.57% | 1,897,383 | Common | SOLE |
| 872381108 | TELA | TELA BIO INC | $4.1M | 0.56% | 2,782,923 | Common | SOLE |
| 002942100 | AARD | AARDVARK THERAPEUTICS INC | $4.1M | 0.55% | 306,912 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $4.0M | 0.53% | 250,606 | Common | SOLE |
| 08205P209 | BNTC | BENITEC BIOPHARMA INC | $3.9M | 0.52% | 276,267 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $3.5M | 0.47% | 88,910 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $3.4M | 0.46% | 141,238 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $3.3M | 0.44% | 230,837 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $3.2M | 0.43% | 108,801 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $3.1M | 0.42% | 720,452 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $3.0M | 0.41% | 80,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $3.0M | 0.40% | 1,368,075 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $2.7M | 0.37% | 51,210 | Common | SOLE |
| 05479K106 | ELUT | ELUTIA INC | $2.5M | 0.34% | 2,850,987 | Common | SOLE |
| 24661P807 | DCTH | DELCATH SYS INC | $2.2M | 0.29% | 203,386 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $2.1M | 0.28% | 50,000 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $2.0M | 0.26% | 653,594 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $2.0M | 0.26% | 166,161 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $1.3M | 0.17% | 100,000 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $1.1M | 0.15% | 70,000 | Common | SOLE |
| 14070B959 | CAPR | CAPRICOR THERAPEUTICS INC | $1.0M | 0.14% | 144,700 | PUT | SOLE |
| 59045L205 | MRSN | MERSANA THERAPEUTICS INC | $1.0M | 0.14% | 133,636 | Common | SOLE |
| 75041J101 | RADX | RADIOPHARM THERANOSTICS LTD | $1.0M | 0.14% | 187,406 | Common | SOLE |
| 002120952 | ATYR | ATYR PHARMA INC | $901,250 | 0.12% | 1,250,000 | PUT | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $806,000 | 0.11% | 50,000 | Common | SOLE |
| 03969T959 | ARCT | ARCTURUS THERAPEUTICS HLDGS | $774,060 | 0.10% | 42,000 | PUT | SOLE |
| 87164F905 | SNDX | SYNDAX PHARMACEUTICALS INC | $769,500 | 0.10% | 50,000 | CALL | SOLE |
| 90400D958 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $752,000 | 0.10% | 25,000 | PUT | SOLE |
| 61559X904 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $466,050 | 0.06% | 65,000 | CALL | SOLE |
| 60785L207 | — | MODULAR MED INC | $447,544 | 0.06% | 639,531 | Common | SOLE |
| 09075X207 | BDSX | BIODESIX INC | $374,533 | 0.05% | 49,607 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $262,500 | 0.04% | 15,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $218,517 | 0.03% | 10,675 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $215,100 | 0.03% | 30,000 | Common | SOLE |
| 03969T109 | ARCT | ARCTURUS THERAPEUTICS HLDGS | $63,491 | 0.01% | 3,445 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $20,769 | 0.00% | 365 | Common | SOLE |
| 77313F114 | RCKTW | ROCKET PHARMACEUTICALS INC | $4,109 | 0.00% | 104,828 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.